IP Library Granted Patent US 10,724,002
Granted Patent B2
US 10,724,002 · App. 15/946,101 · Granted Jul 28, 2020

Erythroid cells producing adult-type beta-hemoglobin generated from human embryonic stem cells

Inventors: Igor I. Slukvin (Verona, WI); James A. Thomson (Madison, WI); Maksym A. Vodyanyk (Madison, WI); Maryna E. Gumenyuk (Madison, WI)
Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
C12N5/0641C12N2500/25C12N2501/125C12N2501/14C12N2501/145C12N2501/23C12N2501/39C12N2502/1394C12N2506/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,724,002
App. No.
15/946,101
Granted
Jul 28, 2020
Kind
B2
Abstract

Methods and compositions of erythroid cells that produce adult β-hemoglobin, generated by culturing CD31+, CD31+/CD34+ or CD34+ cells from embryonic stem cells under serum-free culture conditions.

Claims (14)

1. A method of making a blood product for use in transfusions, the method comprising:

(a) culturing human embryonic stem cells under conditions which favor differentiation of the cells into hematopoietic progenitors;

(b) isolating cells from step (a) selected from the group consisting of CD31+, CD34+, and CD31+/CD34+ cells, wherein the cells are enriched in CD31+/CD43+, CD31+/CD34+, CD34+/CD43+ or CD31+/CD34+/CD43+ hematopoietic progenitors;

(c) culturing in serum free conditions the isolated CD31+, CD31+/CD34+ and CD34+ cells to cause differentiation to erythroid precursor cells, and

(d) self-renewal/expansion and maturation of the erythroid precursor cells to produce a pure population of human erythroid cells, wherein the population of human erythroid cells is CD71+ and produces adult β-hemoglobin and fetal γ-hemoglobin but not embryonic ζ-hemoglobin,

wherein the blood product comprises the isolated human erythroid cells of step (d) and is essentially free of lymphocytes.

2. The method of claim 1 , wherein the blood product does not contain serum.

3. The method of claim 1 , wherein the blood product contains less than 0.1% leukocytes.

4. The method of claim 1 , wherein the culturing of step (c) is in the presence of stem cell factor and erythropoietin under conditions preventing cell adherence.

5. The method of claim 1 , wherein the human embryonic stem cells are co-cultured with stromal cells to produce the hematopoietic progenitors.

6. The method of claim 1 , wherein at least 0.2×105 erythroid cells are generated from one human embryonic stem cell.

7. The method of claim 1 , wherein the cells of step (d), which produce adult-type β-hemoglobin, are CD31−, CD34−, CD71+, CD235a+.

8. The method of claim 1 , wherein the blood product comprises at least 95% live cells that stain positive with antibodies against fetal γ-hemoglobin and adult β-hemoglobin, but do not stain positive with antibodies against embryonic ζ-hemoglobin.

9. The method of claim 8 , wherein the live cells are nucleated erythroid cells.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jun 7, 2018
From: WISCONSIN ALUMNI RESEARCH FOUNDATION
To: THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY
Reel/Frame 047140/0980 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2018
From: THOMSON, JAMES; VODYANYK, MAKSYM; GUMENYUK, MARYNA; SLUKVIN, IGOR
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 045644/0892 →
Continuity (4)
Continuation 13419055 · Mar 13, 2012
Division 11672724 · Feb 8, 2007
Provisional Application 60743264 · Feb 9, 2006
Related Publication 20180230430A1 · Aug 16, 2018